Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. PANW
3. CL
4. SNDK
5. TAP
6. DELL
7. ROIV
8. ANET
9. NKE
10. BLDR

Go back to Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
(NASDAQ: RCKT) Delayed: 3.86 +0.07 (1.85%)
Previous Close $3.79    52 Week High $ 
Open $3.75    52 Week Low $ 
Day High $3.88    P/E N/A 
Day Low $3.73    EPS $ 
Volume 888,541